• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用药核对在处理心动过缓中的作用:药物性窦性心动过缓的罕见原因

Role of Medication Reconciliation in Managing Bradycardia: A Rare Cause of Medication-Induced Sinus Bradycardia.

作者信息

Alhwarat Buthainah, Sawalha Khalid, Alshaghdali Ibrahim, Moustafa Abdelmoniem, Paydak Hakan

机构信息

Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, USA.

Cardiovascular Disease, University of Arkansas for Medical Sciences, Little Rock, USA.

出版信息

Cureus. 2025 Jul 22;17(7):e88550. doi: 10.7759/cureus.88550. eCollection 2025 Jul.

DOI:10.7759/cureus.88550
PMID:40861735
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12372550/
Abstract

Sinus bradycardia is defined as a heart rate of less than 60 beats per minute (bpm), and it can be attributed to many etiologies, some of which are reversible, including but not limited to acute coronary syndrome, active infections, electrolyte imbalances, hypothyroidism, and medications. We report the case of a 64-year-old man who was admitted to the intensive care unit for the management of status epilepticus, where he developed new-onset, life-threatening sinus bradycardia, requiring placement on support with two inotropic agents (epinephrine and dopamine) due to persistent hemodynamic instability. Cardiology was consulted as a result, and after extensive workup, including review of past medical conditions, laboratory testing, and telemetry review, including that for reversible etiologies, we identified one of the antiepileptic agents on his medication list as the culprit of his sinus bradycardia. This case serves to contribute to existing, very limited, clinical data on its adverse cardiovascular effects.

摘要

窦性心动过缓的定义为心率低于每分钟60次(bpm),其可归因于多种病因,其中一些是可逆的,包括但不限于急性冠状动脉综合征、活动性感染、电解质失衡、甲状腺功能减退和药物。我们报告一例64岁男性病例,该患者因癫痫持续状态入住重症监护病房,在那里他出现了新发的、危及生命的窦性心动过缓,由于持续的血流动力学不稳定,需要使用两种血管活性药物(肾上腺素和多巴胺)进行支持治疗。因此心内科会诊,经过广泛检查,包括回顾既往病史、实验室检查和遥测检查,包括对可逆病因的检查,我们确定他用药清单上的一种抗癫痫药物是其窦性心动过缓的罪魁祸首。该病例有助于补充关于其不良心血管影响的现有非常有限的临床数据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/931b/12372550/5857d5d43596/cureus-0017-00000088550-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/931b/12372550/93d1080db1db/cureus-0017-00000088550-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/931b/12372550/580d4ee7a368/cureus-0017-00000088550-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/931b/12372550/44fc9be84fed/cureus-0017-00000088550-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/931b/12372550/5857d5d43596/cureus-0017-00000088550-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/931b/12372550/93d1080db1db/cureus-0017-00000088550-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/931b/12372550/580d4ee7a368/cureus-0017-00000088550-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/931b/12372550/44fc9be84fed/cureus-0017-00000088550-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/931b/12372550/5857d5d43596/cureus-0017-00000088550-i04.jpg

相似文献

1
Role of Medication Reconciliation in Managing Bradycardia: A Rare Cause of Medication-Induced Sinus Bradycardia.用药核对在处理心动过缓中的作用:药物性窦性心动过缓的罕见原因
Cureus. 2025 Jul 22;17(7):e88550. doi: 10.7759/cureus.88550. eCollection 2025 Jul.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
4
Interventions for preventing falls in older people in care facilities.护理机构中预防老年人跌倒的干预措施。
Cochrane Database Syst Rev. 2025 Aug 20;8:CD016064. doi: 10.1002/14651858.CD016064.
5
Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease.手机短信用于心血管疾病二级预防中的药物依从性。
Cochrane Database Syst Rev. 2024 Mar 27;3(3):CD011851. doi: 10.1002/14651858.CD011851.pub3.
6
Automated monitoring compared to standard care for the early detection of sepsis in critically ill patients.与标准护理相比,自动监测用于危重症患者脓毒症的早期检测
Cochrane Database Syst Rev. 2018 Jun 25;6(6):CD012404. doi: 10.1002/14651858.CD012404.pub2.
7
Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty.用于预防激光小梁成形术后眼压暂时升高的围手术期药物。
Cochrane Database Syst Rev. 2017 Feb 23;2(2):CD010746. doi: 10.1002/14651858.CD010746.pub2.
8
Dual-chamber pacemakers for treating symptomatic bradycardia due to sick sinus syndrome without atrioventricular block: a systematic review and economic evaluation.用于治疗无房室传导阻滞的病态窦房结综合征所致症状性心动过缓的双腔起搏器:一项系统评价与经济学评估
Health Technol Assess. 2015 Aug;19(65):1-210. doi: 10.3310/hta19650.
9
Sexual Harassment and Prevention Training性骚扰与预防培训
10
Oral and intranasal aspirin desensitisation for non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease.用于非甾体抗炎药(NSAID)诱发的呼吸道疾病的口服和鼻内阿司匹林脱敏疗法。
Cochrane Database Syst Rev. 2025 Jan 7;1(1):CD013476. doi: 10.1002/14651858.CD013476.pub2.

本文引用的文献

1
Cardiovascular Effects of Antiseizure Medications for Epilepsy.抗癫痫药物对癫痫的心血管影响。
CNS Drugs. 2025 Apr;39(4):383-401. doi: 10.1007/s40263-025-01163-x. Epub 2025 Feb 14.
2
Cardiac adverse events associated with lacosamide: a disproportionality analysis of the FAERS database.与拉考沙胺相关的心脏不良事件:FAERS 数据库的一项比例失调分析。
Sci Rep. 2024 Jul 13;14(1):16202. doi: 10.1038/s41598-024-67209-0.
3
Evaluation of Cardiovascular Concerns of Intravenous Lacosamide Therapy in Epilepsy Patients.癫痫患者静脉注射拉科酰胺治疗中心血管问题的评估
Front Neurol. 2022 Jul 4;13:891368. doi: 10.3389/fneur.2022.891368. eCollection 2022.
4
Lacosamide-Related Arrhythmias: A Systematic Analysis and Review of the Literature.拉科酰胺相关性心律失常:文献的系统分析与综述
Cureus. 2021 Dec 27;13(12):e20736. doi: 10.7759/cureus.20736. eCollection 2021 Dec.
5
Cardiac effects of rapid intravenous loading of lacosamide in patients with epilepsy.癫痫患者快速静脉注射拉科酰胺的心脏效应。
Epilepsy Res. 2021 Oct;176:106710. doi: 10.1016/j.eplepsyres.2021.106710. Epub 2021 Jul 7.
6
Safety of Intravenous Push Lacosamide Compared With Intravenous Piggyback at a Tertiary Academic Medical Center.静脉推注拉考沙胺与在三级学术医疗中心静脉推注相比的安全性。
Ann Pharmacother. 2021 Feb;55(2):181-186. doi: 10.1177/1060028020943569. Epub 2020 Jul 19.
7
Structure and Pharmacology of Voltage-Gated Sodium and Calcium Channels.电压门控钠离子和钙离子通道的结构与药理学
Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:133-154. doi: 10.1146/annurev-pharmtox-010818-021757. Epub 2019 Sep 19.
8
Evaluating and managing bradycardia.评估和管理心动过缓。
Trends Cardiovasc Med. 2020 Jul;30(5):265-272. doi: 10.1016/j.tcm.2019.07.001. Epub 2019 Jul 9.
9
2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society.2018年美国心脏病学会/美国心脏协会/心律学会关于心动过缓和心脏传导延迟患者评估与管理的指南:执行摘要:美国心脏病学会/美国心脏协会临床实践指南工作组及心律学会的报告
J Am Coll Cardiol. 2019 Aug 20;74(7):932-987. doi: 10.1016/j.jacc.2018.10.043. Epub 2018 Nov 6.
10
Lacosamide: A Review in Focal-Onset Seizures in Patients with Epilepsy.拉考酰胺:一项用于癫痫局灶性发作患者的综述。
CNS Drugs. 2018 May;32(5):473-484. doi: 10.1007/s40263-018-0523-7.